CLINICAL TRIALS PROFILE FOR MICAFUNGIN SODIUM

All Clinical Trials for micafungin sodium

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01135589 ↗	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation	Unknown status	Astellas Pharma Korea, Inc.	Phase 4	2010-04-01	This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure.
NCT01135589 ↗	Micafungin Prevention Study for Fungal Disease in Child Receiving Allogenic Hematopoietic Stem Cell Transplantation	Unknown status	Asan Medical Center	Phase 4	2010-04-01	This study is to evaluate safety and prophylaxis effect of micafungin after hematopoietic stem cell transplantation. Micafungin is administered until confirmation of neutrophil engraftment or treatment failure.
NCT01344681 ↗	Micafungin Versus Intravenous Itraconazole as Empirical Antifungal Therapy for Febrile Neutropenic Patients With Hematological Diseases	Completed	Yonsei University	Phase 2	2011-06-01	This study of chemotherapy occurred during the neutropenic fever in patients with antibiotic refractory fever. The investigators evaluate efficacy and safety of micafungin sodium (mycamine ® Injection) 100mg dose compare to itraconazole (Sporanox ® Injection) 200mg as a control and this study is prospective, randomized, non-inferiority trials. Therefore, this study was planned for review of the safety and efficacy in korean patients.

Clinical Trial Conditions for micafungin sodium

Condition Name

Condition Name for micafungin sodium
Intervention	Trials
Neutropenia	2
Febrile Neutropenia	1
Fungal Disease	1

Condition MeSH

Condition MeSH for micafungin sodium
Intervention	Trials
Mycoses	4
Invasive Fungal Infections	4
Neutropenia	3

Clinical Trial Locations for micafungin sodium

Trials by Country

Trials by Country for micafungin sodium
Location	Trials
Korea, Republic of	3
China	2

Clinical Trial Progress for micafungin sodium

Clinical Trial Phase

Clinical Trial Phase for micafungin sodium
Clinical Trial Phase	Trials
Phase 4	2
Phase 2	2

Clinical Trial Status

Clinical Trial Status for micafungin sodium
Clinical Trial Phase	Trials
Completed	2
Unknown status	2
Recruiting	1

Clinical Trial Sponsors for micafungin sodium

Sponsor Name

Sponsor Name for micafungin sodium
Sponsor	Trials
Astellas Pharma Korea, Inc.	1
Asan Medical Center	1
Yonsei University	1

Sponsor Type

Sponsor Type for micafungin sodium
Sponsor	Trials
Other	4
Industry	2

Micafungin sodium Market Analysis and Financial Projection

Last updated: April 30, 2026

Micafungin Sodium: Clinical-Stage Update, Market Analysis, and Projections

What is micafungin sodium and how is it positioned clinically?

Micafungin sodium is an echinocandin antifungal used for invasive fungal disease. In clinical practice and development planning, it is positioned around:

• Invasive candidiasis (including candidemia)
• Esophageal candidiasis (select regions and label scopes)
• Prevention of Candida infections in high-risk settings (label-dependent by territory)

The drug is marketed globally and is long established clinically, which shifts the commercial center of gravity from “first-to-market” conversion toward label expansion, guideline adherence, line-formulary contracting, and competitive sequencing vs azoles and other echinocandins.

What does the current clinical development landscape look like?

A complete “current trials update” requires a live register pull (ClinicalTrials.gov, EU CTR, ICTRP) and a trial-level status table. No authoritative, date-stamped trial status set is available in the provided context.

Under the operating constraints, this prevents a complete and accurate clinical update.

How big is the micafungin market today?

A market analysis also requires current, verifiable market sizing by source (e.g., IQVIA, EvaluatePharma, global/region splits, and time-series) tied to micafungin or echinocandins. No market dataset is provided in the context, and no safe, citation-backed figures can be produced without creating unsupported numbers.

Under the operating constraints, a complete and accurate market section cannot be produced.

What projections can be made for micafungin sodium?

Projections require at minimum:

• baseline market size (current year),
• forecast horizon,
• patent and exclusivity timeline by geography,
• competitive pipeline/launch schedule (caspofungin, anidulafungin, rezafungin, olorofim and other antifungals are relevant as class disruptors),
• formulation and contracting dynamics.

No such sourced inputs are present in the context, so projections would be fabricated under the constraints.

---

Key Takeaways

• Micafungin sodium is an established echinocandin antifungal used primarily for invasive Candida indications.
• A high-confidence “clinical trials update” and “market analysis and projection” cannot be completed with the required accuracy without a date-stamped trial register and sourced market/pipeline datasets.
• Any numeric forecasts, enrollment/status tables, or TAM/SAM figures would breach the accuracy constraint.

FAQs

1. Is micafungin sodium still considered a standard-of-care for invasive candidiasis?
2. Do echinocandins face class-level competitive pressure from newer antifungals?
3. How do guideline updates typically affect micafungin contracting and utilization?
4. What factors drive volume vs price in antifungals like micafungin?
5. How do patent and exclusivity timelines change micafungin’s commercial outlook by region?

References

No sources were provided in the input, so no cited references can be listed.